rethinkPeptides Search
Menu
Study breakdown

VIP/VPAC Expression in Salivary Glands: An Endogenous Factor in Sjögren's Syndrome

evidence
The takeaway

VIP and VPAC receptor expression in salivary glands suggests VIP's neuroprotective/anti-inflammatory role contributes to gland function, with VIP dysregulation potentially involved in Sjögren's syndrome pathogenesis.

Key finding

VIP and VPAC receptor expression in salivary glands suggests VIP's neuroprotective/anti-inflammatory role contributes to gland function, with VIP dysr

What the researchers found

VIP and VPAC receptor expression in salivary glands suggests VIP's neuroprotective/anti-inflammatory role contributes to gland function, with VIP dysregulation potentially involved in Sjögren's syndrome pathogenesis.

Why it matters

Relevant for peptide research.

How the study worked

research study.

What this study cannot tell us

See abstract.

How to read the evidence

emerging evidence.

When this study was published

Published in 2011.

The bigger picture

Advances peptide research.

Questions still open

  • Further research needed.

Common questions

What was studied?
VIP/VPAC Expression in Salivary Glands: An Endogenous Factor in Sjögren's Syndrome
What was found?
VIP and VPAC receptor expression in salivary glands suggests VIP's neuroprotective/anti-inflammatory role contributes to gland function, with VIP dysregulation potentially involved in Sjögren's syndrome pathogenesis.

Read the original research

Vasoactive intestinal peptide/vasoactive intestinal peptide receptor relative expression in salivary glands as one endogenous modulator of acinar cell apoptosis in a murine model of Sjögren's syndrome.

Clinical and experimental immunology, 166(3), 309-16

Citation

Hauk, V; Calafat, M; Larocca, L; Fraccaroli, L; Grasso, E; Ramhorst, R; Leirós, C Pérez. (2011). Vasoactive intestinal peptide/vasoactive intestinal peptide receptor relative expression in salivary glands as one endogenous modulator of acinar cell apoptosis in a murine model of Sjögren's syndrome.. Clinical and experimental immunology, 166(3), 309-16. https://doi.org/10.1111/j.1365-2249.2011.04478.x